MRU, APT Foundation, Inc
New Haven, Connecticut, 06519, United States
NCT Number: NCT02124980
If shown to be effective, the Recovery Line would provide an inexpensive, transportable, and easy to use treatment to improve substance abuse outcomes for medication assisted treatment. Given the high costs of relapse and continued drug use, improvement of treatment outcomes would provide substantial health, economic, and societal benefits.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
New Haven, Connecticut, 06519, United States
Dependence on heroin and prescription pain relievers has almost tripled since 2000, resulting in dramatic increases in opioid dependence treatment admissions. However, among agonist-maintained patients continued drug use is common and associated with high rates of relapse and treatment drop-out. Although counseling has been shown to be effective, it is costly and some patients dislike counseling, others have responsibilities that make attendance difficult, and patients in rural settings often have limited access to psychotherapy. Thus, there is a clear need to develop additional acceptable and cost-effective treatments. Interactive Voice Response (IVR) systems, which have been shown to effectively augment brief interventions for substance abuse, are automated, computer-based systems delivered via phone and use voice or keys to access different menus. IVR systems can be accessed from any phone rather than only specified technology (e.g., smartphones), and offer advantages of low cost, consistent delivery, expanded access, and 24-hour availability of immediate therapeutic intervention. The Recovery Line is a Cognitive Behavioral Therapy (CBT)-based IVR system to reduce substance use in patients receiving opioid agonist maintenance. We recently completed a pilot randomized 4-week trial which showed significant reduction in cocaine use and increased coping skill efficacy, but patients called less time than expected, suggesting methods to improve patient use may further improve efficacy. This Stage Ib application proposes three phases to develop system functions to increase patient system use and to test those functions. The initial two phases will develop customized recommendations and reminders to be used in Phase 3 pilot clinical trial. The Phase 3 trial is a 12-week pilot randomized (N=60), clinical trial with a 3 month post-treatment follow-up to obtain data regarding the feasibility, acceptability and efficacy of the developed Recovery Line (compared to TAU). Efficacy will be evaluated for the two primary outcome domains of the proportion of urine screens negative for illicit drugs and monthly days of illicit drug abstinence. Secondary outcome measures will be retention in treatment and coping skills efficacy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Therapeutic interactive voice response, Therapeutic IVR, TIVR
Time frame: 6 months
bi-weekly urine screens negative for illicit drugs
Time frame: 6 months
monthly days of self reported illicit drug abstinence
Time frame: 6 months
days retained in methadone treatment
Time frame: 6 months
coping behaviors as measured by the Effectiveness of Coping Behavior Inventory and the Drug Risk Response Test
Time frame: 6 months
a semi-structured interview will be used to assess overall satisfaction with methadone services and satisfaction ratings of specific components of treatment
Time frame: 6 months
the Treatment Services Review is a semistructured used to collect detailed information on receipt of health and psychosocial services outside of the study
Yale University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03678051
Chemically-Induced Disorders, Drug Abuse
Richmond, Virginia, United States
View Trial DetailsNCT04581499
Alcohol Dependence, Alcohol Use Disorder
Boston, Massachusetts, United States
View Trial DetailsNCT04003948
Behavior, Behavior, Addictive
Reus, Tarragona, Spain
View Trial DetailsNCT02396979
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
View Trial Details